The clinical spectrum of labile hypertension: a management dilemma.
J Clin Hypertens (Greenwich). 2009;11:491-497. (c)2009 Wiley Periodicals, Inc.Although the management of the labile component of blood pressure elevation is a problem often encountered by clinicians, there is a paucity of information available to guide therapeutic decisions. This review discusses the clinical relevance of blood pressure lability, the limitations of current knowledge, and possible directions for future research and clinical management.
Mann
Samuel J
SJ
Division of Nephrology and Hypertension, Department of Medicine, New York Presbyterian Hospital, Weill/Cornell Medical Center, New York, NY 10021, USA. sjmann@med.cornell.edu
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure; D004232:Diuretics / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000503:physiopathology* / Q000517:prevention & control; D008297:Male
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004232:Diuretics